Abstract
“Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Current Pharmaceutical Design
Title: Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Volume: 14 Issue: 3
Author(s): Mauro Piacentini, Walter Malorni, Maria Grazia Farrace and Carlo Rodolfo
Affiliation:
Abstract: “Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Piacentini Mauro, Malorni Walter, Farrace Grazia Maria and Rodolfo Carlo, Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection, Current Pharmaceutical Design 2008; 14 (3) . https://dx.doi.org/10.2174/138161208783413220
DOI https://dx.doi.org/10.2174/138161208783413220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Platelet Activation Polymorphisms in Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma
Current Drug Safety Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Regional Anesthesia and Analgesia: Their Role in Postoperative Outcome
Current Topics in Medicinal Chemistry Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Acid-Sensing Ion Channels: A Novel Therapeutic Target for Pain and Anxiety
Current Pharmaceutical Design